Compare SRL & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRL | VANI |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 95.8M |
| IPO Year | 1996 | 2014 |
| Metric | SRL | VANI |
|---|---|---|
| Price | $8.61 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 27.0K | ★ 200.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | N/A | ★ 14.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.13 | $0.91 |
| 52 Week High | $10.39 | $1.92 |
| Indicator | SRL | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 33.75 |
| Support Level | $8.66 | N/A |
| Resistance Level | $9.60 | $1.23 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 30.00 | 17.02 |
Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.